gp

GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].

GP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays. GP 1a is approximately 30-fold more selective for CB2 receptors than CB1 receptors and increases P-ERK1/2 expression in HL-60 cells in vitro. GP 1a is beneficial for skin wound healing. GP 1a inhibits inflammation and fibrogenesis while promoting epithelial re-formation.

GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2Db molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM. GP33-41 Epitopeis a strong agonist of CD8 T cells

P-gp inhibitor 1 inhibits reversing P-glycoprotein-mediated multidrug resistance with an EC50 of 57.9 nM (K562/A02 cells).

P-gp Inhibitor 15 (compound 7a), a nonsubstrate inhibitor of P-glycoprotein (Pgp), inhibits Pgp-ATPase activity and interferes with Pgp-mediated Rhodamine123 efflux. Additionally, this compound enhances the inhibitory effect of Paclitaxel on tumor progression in the KBV xenograft tumor model in nude mice [1].

P-gp/BCRP-IN-2 (compound 15), an oxadiazole derivative, functions as a dual inhibitor targeting both the ABC transporter P-glycoprotein (IC50: 1.6 nM) and BCRP (IC50: 600 nM). Additionally, it bolsters the anti-proliferative impact of Doxorubicin in the drug-resistant HT29/DX and MDCK-MDR1 human adenocarcinoma colon cancer cell lines [1].

P-gp Inhibitor 3, an effective P-glycoprotein (P-gp) inhibitor, activates P-gp ATPase to inhibit P-gp's efflux function. It demonstrates a relatively stronger multidrug resistance (MDR) reversal ability, thereby enhancing the anti-tumor efficacy of Paclitaxel.

P-gp/BCRP-IN-1 (compound 19) is a relatively safe, orally active, and efficient inhibitor of the efflux transporters P-gp and BCRP. By inhibiting their efflux function, it reverses resistance and enhances the oral bioavailability of Paclitaxel (PTX) [1].

P-gp inhibitor 4 is a selective P-glycoprotein modulator with an EC 50 of 94 nM. P-gp inhibitor 4 increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

P-gp Inhibitor 2 is a powerful P-glycoprotein (P-gp) inhibitor, effective in reversing Doxorubicin resistance with an IC50 of 0.22 µM in human colorectal carcinoma cells overexpressing P-gp (SW600 Ad300).

GP(33-41) TFA, a 9-amino-acid (aa) peptide, represents the optimal sequence of the lymphocytic choriomeningitis virus GP1 epitope, effectively upregulating H-2D b molecules on the RMA-S (Db Kb) cell surface with a SC 50 value of 344 nM [1].

P-gp modulator 1 is a high affinity and orally available P-glycoprotein (Pgp) modulator

GP-1681, a G-protein coupled receptor (GPCR) agonist, is used potentially for the treatment of influenza infection.

GP-1-515 is an adenosine kinase inhibitor with anti-inflammatory effects.

P-gp Inhibitor 13, a P-glycoprotein antagonist, can counteract paclitaxel resistance in A2780/T cells, proving valuable for advanced acute myeloid leukemia research [1].

P-gp inhibitor 5 is a potent inhibitor of P-glycoprotein (P-gp), inhibiting P-gp by a factor of 2.5 and 3.0 at 1.25 μM and 2.5 μM, respectively. p-gp inhibitor 5 exhibits anti-proliferative effects on some cancer cells. P-gp inhibitor 5 was able to restore cellular sensitivity to Vincristine and Paclitaxel, thereby reversing the multidrug resistant (MDR) phenotype of ABCB1/Flp-InTM-293 and KBvin.

EBOV-GP-IN-1 (Compound 28) is a potent inhibitor of Ebola entry, acting on the Ebola virus envelope glycoprotein (EBOV-GP) (IC50: 0.05 μM).

P-gp modulator 2 (Compound 27) is a potent competitive and metabotropic P-glycoprotein (P-gp) modulator.

LCMV GP (61-80) is a peptide fragment derived from LCMV glycoprotein (GP) and corresponds to amino acids 61-80. This specific epitope, LCMV GP (61-80), has the ability to elicit CD4+ T-cell response.

GP-2B, an antimicrobial peptide, exhibits antibacterial activity against Gram-positive strains, with a minimum inhibitory concentration (MIC) ranging from 8 to 128 μg/mL for S. aureus and Enterococcus faecalis [1].

P-gp modulator 3 (Compound 37) is a potent, competitive, metabotropic P-glycoprotein (P-gp) modulator.

GP2-114 is a catecholamine exercise mimetic that can be used to study coronary artery disease (CAD).

gp120-α4β7 binding inhibitor 11 is an anti-HIV agent. gp120-α4β7 binding inhibitor 11 interferes the binding of HIV associated glycoprotein gp12G with the integrin α4β7 (IC50=1.64nM).

LCMV gp33-41 acetate is a sequence of lymphocytic choriomeningitis virus which restricted by major histocompatibility complex class I H-2Db and presented to cytotoxic T lymphocytes.

Gp100 (25-33) corresponds to residues 25 to 33 of the mouse self/tumor antigen glycoprotein (mgp100), which is an enzyme responsible for pigment synthesis. This epitope fragment is found in both normal melanocytes and melanoma cells.

Diguanoside tetraphosphate (GP4G) is a symmetrical bis-diphospho nucleoside isolated from Artemia salina cysts, serving as an epithelial cell and hair growth regulator [1].

HER2/neu (654-662) GP2 acetate is derived from the human epidermal growth factor receptor 2 (HER2-Neu, 654–662). HER2/neu (654-662) GP2 acetate induces HLA-A2-restricted cytotoxic T lymphocytes reactive to various epithelial cancers.

Arbutamine (GP 21213) is a novel potent non-selective beta-adrenoceptor agonist with alpha-1-sympathomimetic activity.Arbutamine promotes cardiac stress and increases heart rate, cardiac contractility.Arbutamine can be used to study cardiac stress and coronary artery disease

GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.

gp91ds-tat is a useful organic compound for research related to life sciences and the catalog number is T35393.

GP17 is a type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.

Gp91phox ds-tat, a biologically active peptide, functions as an inhibitor of NADPH oxidase assembly.

GP120, HIV-1 MN, a peptide, is utilized in researching HIV infection [1] [2].

gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an CC 50 of 100.90 μM and IC 50 of 2.2 μM. gp120-IN-1 inhibitis gp120-mediated virus enter into cells. gp120-IN-1 has anti-HIV-1 activity. gp120-IN-1 has dose-dependent cytotoxicity in SUP-T1 cells [1].

LCMV gp33-41 (TFA), an 11-amino-acid carboxyl-extended peptide, comprises a lymphocytic choriomeningitis virus sequence that is presented by MHC class I H-2Db molecules to cytotoxic T lymphocytes [1].

gp120-IN-2 (compound 4i) exhibits anti-HIV-1 activity which is a potent inhibitor of HIV-1 gp120 with an IC 50 of 7.5 μM and CC 50 of 112.93 μM. gp120-IN-2 dose-dependently shows cytotoxicity in SUP-T1 cells [1].

GP3269 is a selective, potent, orally active human adenosine kinase (AK) inhibitor (IC50: 11 nM) with anticonvulsant effects in rats.

Motexafin gadolinium, also known as PCI 0120, is a synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating rea

CGP 3466B maleate (Omigapil maleate) is an orally bioavailable GAPDH nitrosylation inhibitor. Omigapil maleate abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease. Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD).

CGP 20376 is a benzothiazole compound, an anthelmintic, with dual dose-dependent modulation of in vitro effects on the respiratory burst of eosinophils and antifibrillatory properties.

Osteogenic Growth Peptide, OGP acetate is a short, naturally occurring 14-mer growth factor peptide found in serum at μM concentrations. Osteogenic growth peptide OGP is a key factor in the mechanism of the systemic osteogenic response to local bone marro

iGP-1 is a mitochondrial sn-glycerol 3-phosphate dehydrogenase (mGPDH) inhibitor that can be used to study obesity.

CGP 78608 hydrochloride is a specific antagonist at the glycine binding site of the NMDA receptor (IC50 = 6 nM). CGP 78608 hydrochloride exhibits anticonvulsant activity. CGP 78608 hydrochloride potentiates GluN1/GluN3A-mediated glycine currents (estimated EC50 = 26.3 nM).

CGP 35949 is an LTD4 antagonist with phospholipase inhibitory activity.

GPS491 has antiviral activity and inhibits HIV-1, adenovirus, and coronavirus replication by altering RNA processing.

CGP-42112 acetate is a potent angiotensin receptor AT2 agonist that inhibits the increase in protein kinase A activity produced by LPS.

GPLGIAGQ acetate is a MMP2-cleavable polypeptide. GPLGIAGQ acetate can be used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy.

CGP-20712 is a selective β 1-adrenoceptor antagonist with an IC50 of 0.7 nM.

CGP 29030A is a new piperazine derivative with analgesic activity and significant inhibitory effect on potentially nociceptive dorsal horn neurons, which can be used to study painful disorders.

CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.